SOBI-003
- Generic Name
- SOBI-003
- Drug Type
- Biotech
- Unique Ingredient Identifier
- ZS87P77DQC
- Background
SOBI-003 is a chemically modified variant of a recombinant human sulfamidase. It is under investigation in clinical trial NCT03811028 (A Study to Assess the Safety, Tolerability, and Efficacy of Long-term SOBI003 Treatment in Pediatric MPS IIIA Patients).
A Study to Assess the Safety, Tolerability, and Efficacy of Long-term SOBI003 Treatment in Pediatric MPS IIIA Patients
- First Posted Date
- 2019-01-22
- Last Posted Date
- 2022-02-25
- Lead Sponsor
- Swedish Orphan Biovitrum
- Target Recruit Count
- 6
- Registration Number
- NCT03811028
- Locations
- 🇺🇸
Children´s Hospital and research center, Oakland, California, United States
🇹🇷Gazi University Hospital, Ankara, Turkey
🇺🇸University of North Carolina hospitals, Chapel Hill, North Carolina, United States
A Study to Assess the Safety and Tolerability of SOBI003 in Pediatric MPS IIIA Patients
- First Posted Date
- 2018-02-06
- Last Posted Date
- 2021-11-19
- Lead Sponsor
- Swedish Orphan Biovitrum
- Target Recruit Count
- 6
- Registration Number
- NCT03423186
- Locations
- 🇺🇸
Childrens's Hospital and Research Center, Oakland, California, United States
🇺🇸University of North Carolina Hospitals, Chapel Hill, North Carolina, United States
🇹🇷Gazi University Hospital, Ankara, Turkey
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.